4-(1-ethyl-piperidin-4-ylidene)-4,9-dihydro-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one | 34580-17-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环七噻吩
• 英文名称: 4-(1-ethyl-piperidin-4-ylidene)-4,9-dihydro-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one
• 英文别名: 2-(1-Ethylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.0 3,7]tetradeca-1(14),3(7),4,19,12-pentaen-8-one；2-(1-ethylpiperidin-4-ylidene)-6-thiatricyclo[8.4.0.03,7]tetradeca-1(14),3(7),4,10,12-pentaen-8-one
• CAS: 34580-17-1
• 化学式: C₂₀H₂₁NOS
• 分子量: 323.459
• InChiKey: OGXRKFXTEBOAFT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  48.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• SYNERGIC PHARMACEUTICAL COMBINATION OF A LEUKOTRIENE-RECEPTOR ANTAGONIST AND AN INVERSE AGONIST OF HISTAMINE H1
  申请人：Amézcua Amézcua, Federico

  公开号：EP3858354A1

  公开（公告）日：2021-08-04

  The present invention relates to a pharmaceutical composition comprising the synergic combination of a leukotriene-receptor antagonist, such as the active substance montelukast and its pharmaceutically acceptable salts, and an inverse antagonist of histamine H1, such as the active substance ketotifen and its pharmaceutically acceptable salts, which are formulated with pharmaceutically acceptable additives and/or excipients and/or vehicles in a single dosing unit to be administered orally, transdermally or by devices for oral or nasal inhalation. The composition is suitable for the treatment of atopic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  本发明涉及一种药物组合物，该组合物包含白三烯受体拮抗剂（如活性物质孟鲁司特及其药学上可接受的盐）和组胺 H1 反拮抗剂（如活性物质酮替芬及其药学上可接受的盐）的协同组合，它们与药学上可接受的添加剂和/或赋形剂和/或载体配制成单一剂量单位，可口服、透皮或通过口腔或鼻腔吸入装置给药。该组合物适用于治疗特应性疾病，如哮喘、过敏性鼻炎和特应性皮炎。